
EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
AIFA Agenzia Italiana del Farmaco EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders EMA’s Committee for Medicinal Products for Human Use (CHMP) has approved measures recommended by the Pharmacovigilance Risk Assessment Committee (PRAC) to minimise the risk of serious side effects with inhibitors of Janus […]